| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Methylglyoxal, 2-Oxopropanal, 2 oxo propanal, MG, Pyruvaldehyde, Methylglyoxal (MG), MG-modified protein |
| Clonality | |
| Concentration | |
| Host | |
| Immunogen | Synthetic Methylglyoxal modified Keyhole Limpet Hemocyanin (KLH). |
| Isotype | |
| Product Type | |
| Reactivity | |
| Shipping | |
| Storage | |
| Target |
Methylglyoxal (MG) is a reactive dicarbonyl compound formed during lipid peroxidation and glycolytic metabolism. It readily reacts with proteins, nucleic acids, and lipids to form advanced glycation end products (AGEs), which accumulate in the brain during aging and neurodegeneration. These AGEs disrupt cellular homeostasis, impair mitochondrial function, and trigger inflammatory responses.
MG-induced DNA crosslinking and protein modification contribute to neuronal dysfunction and apoptosis. Elevated MG levels have been detected in Alzheimer’s disease, Parkinson’s disease, and diabetic neuropathy, linking metabolic stress to neurodegenerative pathology. MG also interferes with synaptic signaling and plasticity, further compromising cognitive function.
Quantification of MG and AGEs in cerebrospinal fluid and plasma serves as a diagnostic tool and a measure of oxidative burden. Targeting MG detoxification pathways, such as the glyoxalase system, holds therapeutic potential for mitigating oxidative stress and preserving neuronal integrity in neurodegenerative diseases.
A 1:1000 dilution of SMC-517 was sufficient for detection of Methylglyoxal in 0.5 µg of Methylglyoxal conjugated to BSA by ECL immunoblot analysis using Goat Anti-Mouse IgG:HRP as the secondary Antibody.
Cite this product varies by variant:
- SMC-517D — Size: 100 ug: Methylglyoxal Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-517D, RRID: AB_2702945)
- SMC-517D-A390 — Size: 100 ug: Methylglyoxal Antibody: ATTO 390 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-517D-A390, RRID: AB_2702946)
- SMC-517D-A488 — Size: 100 ug: Methylglyoxal Antibody: ATTO 488 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-517D-A488, RRID: AB_2702947)
- SMC-517D-A594 — Size: 100 ug: Methylglyoxal Antibody: ATTO 594 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-517D-A594, RRID: AB_2702949)
- SMC-517D-APC — Size: 100 ug: Methylglyoxal Antibody: APC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-517D-APC, RRID: AB_2702955)
- SMC-517D-BI — Size: 100 ug: Methylglyoxal Antibody: Biotin (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-517D-BI, RRID: AB_2702956)
- SMC-517D-FITC — Size: 100 ug: Methylglyoxal Antibody: FITC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-517D-FITC, RRID: AB_2702957)
- SMC-517D-HRP — Size: 100 ug: Methylglyoxal Antibody: HRP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-517D-HRP, RRID: AB_2702958)
- SMC-517D-PCP — Size: 100 ug: Methylglyoxal Antibody: PerCP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-517D-PCP, RRID: AB_2702960)
- SMC-517D-RPE — Size: 100 ug: Methylglyoxal Antibody: RPE (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-517D-RPE, RRID: AB_2702961)
- SMC-517S — Size: 12 ug: Methylglyoxal Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-517S, RRID: AB_2702945)
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
2. Murata-Kamiya, N., Kamiya, H. (2001) Nucleic Acids Res. 29(16): 3433-3438.